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SUMMARY
Elevated levels of C-reactive protein (CRP) are present inmany disease situations includingmalignan-
cies and may contribute to the pathogenesis of cardiovascular disorders. This study was undertaken
in a myeloma setting to determine whether CRP affects tumor cell growth and survival. We show that
CRP enhanced myeloma cell proliferation under stressed conditions and protected myeloma cells
from chemotherapy drug-induced apoptosis in vitro and in vivo. CRP binds activating Fcg receptors;
activates PI3K/Akt, ERK, and NF-kB pathways; and inhibits caspase cascade activation induced by
chemotherapy drugs. CRP also enhanced myeloma cell secretion of IL-6 and synergized with IL-6
to protect myeloma cells from chemotherapy drug-induced apoptosis. Thus, our results implicate
CRP as a potential target for cancer treatment.INTRODUCTION
C-reactive protein (CRP), the first acute-phase protein
described and an ancient and highly conserved protein
of the pentraxin family, has five identical subunits forming
a planar ring that confers very high stability to the protein.
In healthy young adults, the median concentration of CRP
is 0.8 mg/l, but following an acute-phase stimulus, values
may increase by 10,000-fold, from less than 50 mg/l to
more than 500 mg/l (Pepys and Hirschfield, 2003; Stein
et al., 2000). Plasma CRP is produced primarily in the liver
and synthesized by hepatocytes in response to intermedi-
ary inflammatory cytokines such as IL-1 and IL-6. CRP
has been shown to bind to a variety of ligands, including
pneumococcal polysaccharides, membrane phospho-
lipids, apoptotic cells, fibronectin, and ribonuclear parti-252 Cancer Cell 12, 252–265, September 2007 ª2007 Elseviercles (Stein et al., 2000). CRP also binds C1q and activates
the classical complement cascade and binds Fcg recep-
tors (FcgRs) leading to indirect (via classical complement)
and direct opsonization (via FcgRs) (Stein et al., 2000).
Through these mechanisms, CRP can play a direct role in
a wide range of inflammatory processes and contributes
to innate host immunity.
CRP is a sensitive systemic marker of inflammation and
tissue damage. Elevated levels of CRP are present in
patients with infections, inflammatory diseases, necrosis
such as myocardial infarction (Pepys, 1983), or malignan-
cies including multiple myeloma (MM) (Bataille et al.,
1992; Tienhaara et al., 1994), lymphoma (Legouffe et al.,
1998; Pedersen and Bergmann, 2003), and carcinoma
(Reichle et al., 2004). Accumulating evidence has strongly
suggested that in cardiovascular disease CRP is not only aSIGNIFICANCE
C-reactive protein (CRP) is a sensitive systemicmarker of inflammation and tissue damage. Elevated levels of CRP
are detected in many diseases, and CRP may contribute to the pathogenesis of cardiovascular disorders. These
findings led to our hypothesis that CRP may have a functional role in tumor cells since elevated levels of CRP are
present in cancer patients. This study shows that CRP enhanced myeloma cell proliferation under stressed con-
ditions and protected myeloma cells from chemotherapy drug-, IL-6 withdrawal-, or serum deprivation-induced
apoptosis in vitro and in vivo. Thus, our results provide strong evidence for the effect of CRP on tumor cell
apoptosis and implicate CRP as a potential target for cancer treatment.Inc.
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CRP Protects Myeloma Cells from Apoptosismarker of inflammation but also contributes to pathogene-
sis of the disease (Venugopal et al., 2005). Evidence in-
cludes the results that CRP directly activated various vas-
cular cells to secrete cytokines, enhanced their expression
of adhesion molecules, increased monocyte/macrophage
chemotaxis and adhesion, facilitated extracellular matrix
remodeling, enhanced endothelial dysfunction, and acti-
vated coagulation (for review, see Berenson et al., 2006;
Garcia et al., 2003). Furthermore, human CRP has been
shown to increase myocardial and cerebral infarct size
in rats subjected to coronary or cerebral artery ligation,
respectively, and this drastic enhancement of infarct size
by human CRP was completely abrogated by in vivo com-
plement depletion of the rats usingcobra venom factor (Gill
et al., 2004; Griselli et al., 1999). These findings led to our
hypothesis that CRP may also have a functional role in
tumor cells since elevated levels of CRP are present in
cancer patients (Bataille et al., 1992; Legouffe et al., 1998;
Pedersen and Bergmann, 2003; Tienhaara et al., 1994).
The present study was undertaken in a myeloma setting
to determine whether CRP might affect tumor cell growth
and survival. Our study identifies CRP as an important
protector of myeloma cell apoptosis.
RESULTS
CRP Protects Myeloma Cells from Apoptosis
To examine the effects of CRP on myeloma cells, different
concentrations of highly purified human natural CRP
(nCRP; >98% purity by SDS-PAGE) or recombinant CRP
(rCRP) from Calbiochem-Novabiochem (La Jolla, CA),
dialyzed extensively against PBS to remove sodium azide,
were added to cultures of myeloma cell lines ARP-1,
MM.1S, U266, and MM1-144, and cell proliferation was
examined 48 hr later by 3H-thymidine incorporation assay.
The purity of these proteins was verified by our own assay
(see Figure S1A in the Supplemental Data available with
this article online). The presence of CRP at concentrations
as high as 50 mg/ml did not affect myeloma cell prolifera-
tion (Figure S1B andS1C). Similarly, CRPdid not affect the
survival of myeloma cells measured by Annexin-V binding
(Figure S1D) and TUNEL (data not shown) assays in cells
cultured for 48 hr. However, the addition of CRP to cul-
tures of primary myeloma cells, which otherwise undergo
spontaneous apoptosis ex vivo, significantly enhanced
cell proliferation (Figure 1A) and reduced cell death, as
shown by the results comparing myeloma cells from two
patients (p < 0.05 to p < 0.01; Figure 1B) and the pooled
results using cells from 8 other MM patients (p < 0.05 to
p < 0.01; Figure 1C), although the degree of protection
varied among patients. Myeloma cells likely did not pro-
duce CRP because no detectable CRP protein was found
in their culture supernatants by ELISA. Because both
nCRP and rCRP had almost identical effects on myeloma
cells, nCRP was used in the following experiments.
As the previous data indicated that CRP affected cell
proliferation and survival under stress conditions, we in-
vestigated the effects of CRP on stressed myeloma cell
lines. First, we examined whether CRP protects myelomaCancecells from serum starvation-induced apoptosis. As shown
in Figure 2A, a dose-dependent reduction of apoptosis
was observed in the four myeloma cell lines in cultures
deprived of serum with the addition of CRP. The protect-
ing effects of CRP were detected at a concentration as
low as 10 mg/ml, and at 50 mg/ml, CRP protected up to
70% of myeloma cells from apoptosis induced by serum
starvation (p < 0.05 to p < 0.01). Increasing CRP concen-
trations to a maximum of 100 mg/ml did not show greater
effects on the cells (data not shown). We selected this
range of concentrations of CRP for these experiments be-
cause these concentrations are present in cancer patients
(Fassas et al., 2005; Hara et al., 2000; Legouffe et al.,
1998). Next, we tested two IL-6-dependent myeloma cell
lines XG1 and ANBL-6 and observed the same protective
effects of CRP on apoptosis induced by IL-6 withdrawal
(p < 0.05 to p < 0.01; Figure 2B). More importantly, CRP
also protected, with the similar efficacy, myeloma cells
from dexamethasone- (p < 0.05 to p < 0.01; Figure 2C)
and melphalan-induced apoptosis of myeloma cell lines
(p < 0.05 to p < 0.01; Figure 2D). We also examined the
effects ofCRPonprimarymyelomacells in a coculturewith
osteoclasts since we have shown that osteoclasts were
able to sustain myeloma cell survival ex vitro (Yaccoby
et al., 2004; Yang et al., 2006). Primary myeloma cells
from patients were isolated and cultured for 48 hr in the
presence of melphalan, with or without addition of CRP.
As shown in Figure 2E, significantly fewer apoptotic mye-
loma cells were recovered from cultures with the addition
of melphalan and CRP (p < 0.05, compared with melpha-
lan-treated cultures). Similar results were also obtained
in cocultures of primary myeloma cells with bone marrow
stromal cells (BMSCs; data not shown). As CRP products
contained low levels of endotoxin (LPS: 0.002–0.005 EU/
mg) detected by the Limulus assay, experiments were per-
formed to exclude the possibility that endotoxin mediated
the effects. As shown in Figure 2F, addition of LPS to the
cultures or use of boiled CRP failed to protect myeloma
cells from dexamethasone-induced apoptosis. Likewise,
human serum amyloid P component, which is a closely
related pentraxin protein circulating in human plasma,
had no such effects. Thus, the results clearly demonstrate
the ability of CRP, but not other contaminants or proteins,
to protect myeloma cells from apoptosis in vitro.
CRP Binds FcgR on Myeloma Cells
CRP shares several functional similarities with IgG, includ-
ing complement activation and binding to FcgR (Stein
et al., 2000). It is well documented that CRP binds to FcgRI
(CD64) (Crowell et al., 1991; Marnell et al., 1995), FcgRII
(CD32) (Bharadwaj et al., 1999; Stein et al., 2000), and
probably FcgRIII (CD16) (Khreiss et al., 2002). To examine
whether FcgRs serve as cell surface receptors for CRP on
myeloma cells, we first determined whether and which of
these receptors are expressed by myeloma cells (mono-
clonal antibodies [mAbs]; FcgRI, clone 10.1; FcgRII, clone
7.3; FcgRIII, clone 3G8; and isotype controls were pur-
chased from BD PharMingen, San Diego, CA). As shown
in Figure 3A, all of these FcgRs were detected on ther Cell 12, 252–265, September 2007 ª2007 Elsevier Inc. 253
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CRP Protects Myeloma Cells from ApoptosisFigure 1. CRP Enhances the Proliferation and Reduces Apoptosis of Primary Myeloma Cells Ex Vivo
(A) Proliferation, determined by 3H-thymidine incorporation assay, of freshly isolated myeloma cells from 4 MM patients in 48 hr cultures with the
addition of various concentrations of human natural CRP.
(B) Representative histograms showing the percentages of apoptotic myeloma cells from 2 patients in 48 hr cultures with or without (medium) the
addition of CRP (25 mg/ml).
(C) Percentages of apoptotic myeloma cells from other 8MMpatients in 48 hr cultures with or without (medium) the addition of CRP (25 mg/ml). nCRP,
natural CRP; rCRP, recombinant CRP. *p < 0.05; **p < 0.01. Error bars, SEM.surface of the myeloma cells. These receptors were also
detected, with similar densities, on other myeloma cell
lines including ARK, MM.1R, RPMI-8266, and CAG, and
on primary myeloma cells from eight patients examined
(data not shown). Next, immunoprecipitation with mAbs
against CRP (R&D Systems, Minneapolis, MN) or mAbs
against FcgRs was used to examine whether and which
FcgRs bound to CRP on myeloma cells. As shown in Fig-
ure 3B, immunoprecipitation with mAbs against FcgRII,
but not FcgRI or FcgRIII or isotype controls (data not
shown), produced a strong band of CRP protein visualized
by anti-CRP antibody, whereas all the three mAbs, but not
isotype controls (data not shown), immunoprecipitated
their corresponding receptors. Likewise, mAbs against
CRP also precipitated FcgRII but not FcgRI or FcgRIII (Fig-
ure 3C). To further confirm the binding of CRP to FcgRs,
myeloma cells were incubated with CRP and various con-
centrations of the F(ab0)2 fragments of the FcgR mAbs254 Cancer Cell 12, 252–265, September 2007 ª2007 Elsevier In(Fitzgerald Industries International, Inc., Concord, MA) or
IgG controls, followed by extensive washing and incuba-
tion with FITC-conjugated anti-CRP antibody. As shown
in Figure 3D, mAb 7.3 (FcgRII), but not other mAbs (data
not shown) or mouse IgG, inhibited CRP binding to mye-
loma cells in a dose-dependent manner. Furthermore,
we showed that the F(ab0)2 fragments of blocking mAbs
against CRP or FcgRII (mAb 7.3), but not FcgRI, FcgRIII,
or IgG controls (data not shown), completely abrogated
the protective effects of CRP on dexamethasone-induced
apoptosis of myeloma cells (Figure 3E). To examine the
clinical relevance of CRP, we stained bone marrow biop-
sies of myeloma patients. As shown in Figure 3F, bone
marrow myeloma cells from all five randomly selected,
newlydiagnosedpatientswere strongly stained for surface
CRP, whereas normal control marrow biopsies were not
stained. These findings indicate that circulating, liver-
derived CRP is indeed accumulating on the surface ofc.
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CRP Protects Myeloma Cells from ApoptosisFigure 2. CRP Protects Established Myeloma Cell Lines and Primary Myeloma Cells from Induced Apoptosis In Vitro
Shown are the percentages of apoptotic cells detected by Annexin-V–binding assay in 48 hr cultures in the presence of various concentrations of
CRP. Apoptosis was induced by (A) serum starvation (medium containing no serum) in four myeloma cell lines; (B) IL-6 withdrawal in two IL-6-
dependent myeloma cell lines; (C) dexamethasone (10 mM) or (D) melphalan (5 mM) treatment in four myeloma cell lines; and (E) melphalan (5 mM)
in primary myeloma cells isolated from 4 MM patients (Pt1–Pt4) in cocultures with osteoclasts with or without addition of CRP (25 mg/ml). Cocultures
with medium alone served as control. Details are described in the Experimental Procedures. Similar results were also obtained in cocultures of the
primary myeloma cells with BMSCs. (F) Effects of CRP (25 mg/ml), boiled CRP (bCRP, 100C for 2 hr; 25 mg/ml), LPS (1 ng/ml; Sigma), and serum
amyloid P component (SAP; 25 mg/ml; Sigma) on dexamethasone (10 mM)-induced apoptosis in myeloma cells ARP-1 and MM.1S. Higher concen-
trations of LPS (up to 50 ng/ml) or SAP (up to 100 mg/ml) were also used and showed no protective effects on cell apoptosis (data not shown). The
same results were also obtained by TUNEL assay. Results of three independent experiments are shown. Error bars, SEM.myeloma cells in vivo. Taken together, these results clearly
show that CRPmediates its effect via binding to FcgRII on
myeloma cells. These results were verified with both mye-
loma cell lines and primary myeloma cells from patients.
Human FcgRII contains either an ITAM (immunorecep-
tor tyrosine-based activation motif) or an ITIM (immunore-
ceptor tyrosine-based inhibitory motif) in its intracellular
tail (Xiu et al., 2002), depending on the isoform. FcgRIIACancand FcgRIIC are activating receptors because they con-
tain an ITAM motif, whereas FcgRIIB is an inhibitory re-
ceptor due to its ITIM motif (Xiu et al., 2002). As CRP pref-
erentially binds FcgRII, we wanted to know which of these
receptors are responsible for CRP-mediated signaling in
myeloma cells. Using western blot analysis with specific
antibodies (FcgRIIA, N20; FcgRIIB, C-20; FcgRIIC, P-18;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), weer Cell 12, 252–265, September 2007 ª2007 Elsevier Inc. 255
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CRP Protects Myeloma Cells from ApoptosisFigure 3. Expression of Surface FcgRs and Their Binding to CRP on Myeloma Cells
(A) Flow cytometry analysis showing the expression of FcgRI (CD64), FcgRII (CD32), and FcgRIII (CD16) on four myeloma cell lines.
(B and C) Immunoprecipitation (IP) using antibodies against FcgRs (B) or CRP (C) in myeloma cells treated with or without CRP (25 mg/ml). Blotting
antibodies (WB) used were against CRP or FcgRs. Shown are results obtained with myeloma cell line ARP-1.
(D) Inhibitory effects of the F(ab0)2 fragments of anti-FcgRII mAb (clone 7.3) on CRP (25 mg/ml) binding to myeloma cells APR-1 andMM.1S. Myeloma
cells were incubated with CRP (25 mg/ml) and various concentrations of the F(ab0)2 fragments of the FcgRmAbs or IgG controls, followed by extensive
washing and incubation with FITC-conjugated anti-CRP antibody. F(ab0)2 fragments of mouse IgG served as control. Isotype control represents cells
staining with FITC-conjugated anti-CRP antibody. MFI, mean fluorescence intensity. Same results were obtained with other cell lines and primary
myeloma cells.
(E) Effects of CRP and FcgR blocking antibody F(ab0)2 fragments (20 mg/ml) on CRP (25 mg/ml)-mediated protection of dexamethasone (10 mM)-
induced apoptosis in myeloma cells. Results of three independent experiments are shown.
(F) Staining for CRP in bone marrow biopsies of five randomly selected MM patients (Pt1–Pt5) and one representative normal control (N) out of four
examined by immunohistochemistry with mAb against CRP and conjugated secondary antibody. The insert on the panel for Pt1 shows a represen-
tative control staining with conjugated secondary antibody without the primary anti-CRP mAb. Scale bar, 20 mM. Error bars, SEM.found that myeloma cells commonly express FcgRIIA and
FcgRIIC, whereas normal B cells, 1 out of 10 myeloma cell
lines, and 4 out of 9 primary myeloma cells express
FcgRIIB (Figure 4A). Surface expression of these FcgRIIs256 Cancer Cell 12, 252–265, September 2007 ª2007 Elsevier Iwas confirmed by staining the cells with PE- or FITC-con-
jugated mAbs (clone IV.3 for FcgRIIA; FLI8.26 for FcgRIIA/
IIB, StemCell Technologies, Tukwila, WA; and 7.3 for
FcgRIIs, data not shown). As FcgRIIB was absent fromnc.
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CRP Protects Myeloma Cells from Apoptosismost of themyeloma cell lines and primary myeloma cells,
it is likely that the activating FcgRIIA and/or FcgRIIC are
themajor receptors for CRP. Indeed, immunoprecipitation
using antibodies against either FcgRIIA, FcgRIIC, or CRP,
but not IgG controls (data not shown) revealed that, on
APR-1 cells that express both FcgRIIA and FcgRIIC,
CRP was associated with both of these receptors (Fig-
ure 4B). On MM1-144 cells that express FcgRIIB and
FcgRIIC,CRPwaspredominantly associatedwith FcgRIIC
but not FcgIIB (Figure 4C). These results were verified with
patient-derived primary myeloma cells on which both
FcgRIIA/C and FcgIIB were expressed.
We also examined the functional role of FcgRII in CRP-
mediated protection of myeloma cell apoptosis. First, we
used the F(ab0)2 fragments of mAb specific for FcgRIIA
(IV.3), a blocking antibody specific for both FcgRIIA and
FcgRIIC (C-17, Santa Cruz Biotechnology) or an antibody
specific for FcgRIIB (AF1330, R&D Systems) to disrupt the
interactionofCRPwith the receptorsonARP-1 (expressing
FcgRIIA and FcgRIIC), MM.1S (expressing FcgRIIC), and
MM1-144 (expressing FcgRIIB and FcgRIIC). As shown in
Figure 4D, addition of FcgRIIA/C-antibody F(ab0)2 frag-
ments abrogated CRP-mediated protection of myeloma
cell apoptosis induced by dexamethasone in all three cell
lines tested, whereas addition of the F(ab0)2 fragments of
FcgRIIB-specific antibody or IgGcontrols (data not shown)
to MM1-144 had no effect. F(ab0)2 fragments of IV.3 only
partially abrogated CRP-mediated protection of ARP-1
and had no effect onMM.1S orMM1-144 cells. Next, small
interfering RNAs (siRNAs) for FcgRII genes were synthe-
sized and used to knock down the receptor expression in
myelomacells.Receptor-specificsiRNAssuccessfully and
significantly (70%–80%) knocked down the expression of
FcgRIIC in MM.1S (Figure 4E), FcgRIIA, and/or FcgRIIC in
ARP-1 (Figure 4F), and FcgRIIB and/or FcgRIIC in MM1-
144 (Figure 4G), respectively, on day 3 after transfection
without affecting theexpression level ofFcgRIorother irrel-
evantFcgRII in thecells,which remainedat low levels for up
to 7 days (data not shown). Mock transfection or control
siRNA had no effects. As shown in Figures 4E–4G, knock-
down of FcgRIIC on MM.1S, both but not FcgRIIA or
FcgRIIC individually on ARP-1, or FcgRIIC but not FcgRIIB
on MM1-144 cells completely abrogated CRP-mediated
protection of apoptosis induced by dexamethasone. As
expected, all of these treatments killed a small percentage
of cells (Caplen and Mousses, 2003). These results
confirmed our findings that FcgRIIA and FcgRIIC, but
not FcgRIIB, appear to be the major receptors for CRP
and indicate that both FcgRIIA and FcgRIIC, when co-
expressed, could bind to CRP and generate signaling
to the cells.
Having identified the receptors for CRP, we sought to
elucidate cell-signaling pathways responsible for CRP-
mediated protection of myeloma cell apoptosis. We fo-
cused on the PI3K/Akt, mitogen-activated protein (MAP)
kinase, andNF-kBpathways, as theseare thedownstream
kinases of ITAM (Xiu et al., 2002) and are essential for cell
growth and survival (Franke et al., 1997). First, we exam-
ined the impact of CRP on these pathways in myelomaCanccells without induction of apoptosis. As shown in Fig-
ure 5A, binding of CRP increased the protein levels of
phosphorylated Akt (pAkt) and pERK and activated
NF-kB in the cells, which was evident by increased IkBa
phosphorylation and NF-kB subunit p65 translocation
into nuclei (detected as nuclear p65; np65). The level of
nonphosphorylated Akt and ERK and total NF-kB p65
(tp65) remained unchanged. In the presence of antibody
against FcgRII, but not control IgG (data not shown), the
activation of Akt, ERK, and NF-kB (pIkBa) was inhibited
(Figure 5B). On the other hand, CRP downregulated the
expression of phosphorylated p38 (pp38) and had no
effect on JNK (Figure 5A). To verify these results, we
used PI3K-specific inhibitors LY294002 and wortmannin,
MEK-specific inhibitor PD98059, an IkBa-specific inhibi-
tor, and anNF-kB inhibitor, which blocksNF-kB transloca-
tion into nuclei (all purchased from Calbiochem-Novabio-
chem). As shown in Figure 5C, these inhibitors indeed
inhibited CRP-induced Akt and ERK phosphorylation and
NF-kB subunit p65 translocation into nuclei, respectively.
Furthermore, inhibitors to PI3K (LY294002 and wortman-
nin) andMEK (PD98059) completely abrogated theprotec-
tive effects of CRP on dexamethasone-induced apoptosis
in myeloma cells, whereas treatment of the cells with the
inhibitors alone did not affect their viability (Figure 5D).
Interestingly, the IkBa and NF-kB inhibitors only partially
abrogated CRP-mediated protection of myeloma cell
apoptosis. Altogether, these results indicate that CRPpro-
tects myeloma cells from apoptosis via binding to surface
FcgRII, activating the PI3K/Akt, ERK, and NF-kB path-
ways, and inactivating the p38 pathway.
To investigate the effects of CRP on downstream cas-
pase cascades, activation and cleavage of caspase-9,
-8, -3, and subsequent cleavage of poly (ADP-ribose)
polymerase (PARP) in myeloma cells treated with or with-
out (medium control) dexamethasone in the presence or
absence of CRP were detected by western blotting with
specific antibodies. As shown in Figure 6A, activation and
processing of caspase-9, but not caspase-8, and cleav-
age of caspase-3 and PARP were observed in myeloma
cells treated with dexamethasone. CRP significantly re-
duced dexamethasone-induced activation and process-
ing of caspases (-9, -3) and PARP in the cells (protein
quantification data are shown in Figure 6B). We also
examined the involvement of mitochondria-associated
pro- and antiapoptosis proteins, because the intrinsic ap-
optosis pathwaywas activated in dexamethasone-treated
cells. As shown in Figure 6C, dexamethasone treatment in-
creased the expression of proapoptotic proteins Bad and
Bax and decreased that of phosphorylated Bad (pBad).
Furthermore, dexamethasone also downregulated antia-
poptotic protein Bcl-xL and upregulated phosphorylated
Bcl-2 (pBcl-2), all of which favor the induction of apoptosis
via increased permeability of mitochondria (Srivastava
et al., 1998; Zha et al., 1996). CRP partially but significantly
abrogated dexamethasone-induced upregulation of pBcl-
2 and Bax and restored the expression of pBad andBcl-xL
(Figure 6D), resulting in protection of the cells from
apoptosis.er Cell 12, 252–265, September 2007 ª2007 Elsevier Inc. 257
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CRP Protects Myeloma Cells from ApoptosisFigure 4. Expression and Role of Surface FcgRIIs on CRP-Mediated Protection of Myeloma Cell Apoptosis
(A) Western blot analysis showing protein expression of FcgRIIA, FcgRIIB, and FcgRIIC by normal blood B cells from two healthy blood donors, 10
myeloma cell lines, and purified primary myeloma cells from 9MM patients. Immunoprecipitation (IP) using (B) antibodies against FcgRIIA or FcgRIIC
(upper panel) and antibody against CRP (lower panel) in ARP-1 cells, or (C) antibodies against FcgRIIB or FcgRIIC (upper panel) and antibody against
CRP (lower panel) inMM1-144 cells treatedwith or without CRP (25 mg/ml). Blotting antibodies (WB) usedwere against CRP or FcgRIIs. Similar results
were obtained from other myeloma cell lines and primary myeloma cells. Results of five independent experiments are shown. (D) Effects of FcgRIIA,
FcgRIIA/C, or FcgRIIB blocking antibody F(ab0)2 fragments (20 mg/ml) on CRP (25 mg/ml)-mediated protection of dexamethasone (10 mM)-induced
apoptosis in myeloma cell lines. As ARP-1 and MM.1S do not express FcgRIIB, no experiments were performed with FcgRIIB blocking antibody on258 Cancer Cell 12, 252–265, September 2007 ª2007 Elsevier Inc.
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CRP Protects Myeloma Cells from ApoptosisCRP Synergizes with IL-6 in Protecting
Myeloma Cells from Apoptosis
IL-6 is an important survival cytokine formyeloma (Kawano
et al., 1988), and previous studies demonstrated that IL-6
protected myeloma cells from dexamethasone-induced
apoptosis (Hardin et al., 1994). Therefore we examined
the relationship of CRP with IL-6 in myeloma cell survival.
By ELISA we measured IL-6 secretion by myeloma cells
treated with or without dexamethasone and/or CRP. As
shown in Figure S2A, myeloma cells such as cell lines
MM.1S and ARP-1 constitutively secrete a low amount of
IL-6 (<20 pg/ml), which could be elevated by treatment
with dexamethasone alone or in combination with CRP
(p < 0.05). CRP alone did not upregulate secretion of IL-6.
Next we added exogenous IL-6 (5 ng/ml) or IL-6 in combi-
nation with IL-6 and IL-6 receptor neutralizing antibodies
to cell cultures to examine the effects of IL-6 and IL-6 neu-
tralization and blockade on IL-6- and/or CRP-mediated
protection of myeloma cell apoptosis. As shown in Fig-
ure S2B, although the blocking antibodies, but not IgG
controls (data not shown), completely abrogated the effect
of IL-6, they had no effect on CRP-mediated protection of
myeloma cell apoptosis. Moreover, the combination of
CRPand IL-6 protected agreater number ofmyelomacells
from dexamethasone-induced apoptosis than either CRP
or IL-6 alone. We also compared the effects of CRP, IL-6,
and BMSCs on dexamethasone-induced apoptosis of
primary myeloma cells and showed that CRP-mediated
protection is comparable to protection mediated by IL-6
or BMSCs (Figure S2C). These results indicate that IL-6
was not responsible for CRP-mediated protection of mye-
loma cell apoptosis. Under stress conditions, CRP en-
hancesmyeloma cell secretion of IL-6, which in turn syner-
gizes with or is additive to CRP in protecting myeloma
cells from apoptosis.
In Vivo Effects of CRP on Established Myeloma
To investigate the in vivo effects of CRP on myeloma cell
apoptosis, we inoculated severe combined immunodefi-
cient (SCID) mice subcutaneously with myeloma cell lines
ARP-1 or MM.1S and monitored tumor development.
When palpable tumors (R10 mm in diameter) developed,
mice were treated with intraperitoneal injections of either
dexamethasone (1 mg per mouse daily for 6 consecutive
days), or melphalan (0.5 mg per mouse daily for 6 consec-
utive days). The doses and treatment schedules were
modeled after typical treatment regimens for myeloma
patients (Alexanian et al., 1992; Barlogie et al., 1986); pro-
longed treatments with the drugs would not be possible
due to their toxicities. In some mice, CRP (200 mg perCancmouse) was injected around subcutaneous tumors prior
to each chemotherapy treatment. Results showed that,
compared with controls (PBS-treated mice), treatment
with dexamethasone (Figures 7A and 7C) or melphalan
(Figures 7B and 7D) significantly reduced tumor burdens
and retarded tumor growth, measured as tumor volumes
(Figure 7) and levels of circulating M-proteins (Figure S3)
secreted by the myeloma cells. However, injection of CRP
protected tumors and undermined the therapeutic effects
of these chemotherapy drugs, evident by the significantly
greater tumor burdens in CRP- and dexamethasone- (Fig-
ures 7A and 7C; p < 0.01), or CRP- and melphalan-treated
SCID mice (Figures 7B and 7D; p < 0.01 and p < 0.05) and
in CRP- and melphalan-treated SCID-hu mice (Figure 7E;
p < 0.01) comparedwithmice treatedwith the drugs alone.
Treatment with CRP alone did not affect tumor growth in
SCID or SCID-hu mice. Altogether, these results indicate
that CRP could effectively protect against myeloma cell
apoptosis in vitro and in vivo.
To confirm whether CRP utilizes the same mechanisms
of apoptosis protection in tumor cells in vivo, tumor-bear-
ing mice were sacrificed after treatment, and tumors were
removed for immunohistochemical analysis. As shown
in Figure 8A, injections of CRP led to binding of CRP to
the tumor cells and upregulation and activation of pAkt
and pERK in myeloma-bearing mice. Moreover, injection
of CRP prior to each chemotherapy treatment resulted in
inhibited cleavage of caspase-9 and caspase-3 and re-
duced numbers of apoptotic myeloma cells induced by
dexamethasone (Figure 8B). Hence, these results vali-
dated the mechanisms of CRP-induced signaling and
antiapoptosis in tumor cells.
DISCUSSION
The aim of this study was to examine whether human CRP
could affect tumor cell growth and survival. We modeled
this in myeloma and discovered that addition of CRP to
cultures at levels seen in patients with MM or other tumors
promoted myeloma cell proliferation under stressed con-
ditions and protected myeloma cells from chemotherapy
drug-, IL-6 withdrawal-, or serum deprivation-induced ap-
optosis in vitro. The protective effect was verified in vivo in
myeloma SCID and SCID-hu mouse models. These phe-
nomena may be clinically relevant since CRP was found
accumulate on the surface of bone marrow myeloma
cells from patients with MM. Although myeloma cells ex-
pressed all three types of FcgR, we identified FcgRII, more
specifically FcgRIIA and FcgRIIC, as the primary recep-
tors for CRP on the tumor cells. Our results demonstratedthese two cell lines. nd, not done. Knockdown of surface FcgRIIs by FcgRII-specific siRNA and its effect on CRP-mediated protection of dexameth-
asone-induced apoptosis in (E) MM.1S (expressing FcgRIIC), (F) ARP-1 (expressing FcgRIIA and FcgRIIC), or (G) MM1-144 (expressing FcgRIIB and
FcgRIIC) cells. Controls included mock control, transfection of the cells with control siRNA (control), and detection of FcgRI protein expression. The
upper panels represent percentages of specific apoptosis and lower panels represent protein expression detected by western blot analysis. In these
experiments, cells were transfected with 400 nM siRNA and, 72 hr later, washed and incubated with or without dexamethasone (10 mM) and/or
CRP (25 mg/ml) for 48 hr. Apoptosis was detected by Annexin-V-binding assay. Representative results of three independent experiments are shown.
Error bars, SEM.er Cell 12, 252–265, September 2007 ª2007 Elsevier Inc. 259
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Western blot analysis showing (A) protein levels of phosphorylated (p) and nonphosphorylated Akt, ERK, IkBa, p38, JNK, and the nuclei (np65) or total
(tp65) NF-kB p65 in CRP-treated myeloma cell lines MM.1S and ARP-1 cells for various times. M, minutes. (B) FcgRII antibody inhibited CRP-me-
diated activation of Akt, ERK, and NF-kB (pIkBa). ARP-1 cells were treated with CRP in the presence of F(ab0)2 fragments (20 mg/ml) of antibody
against FcgRII (mAb 7.3) or control IgG (data not shown) for 180 min, and cell lysates were prepared for analysis. Effects of kinase inhibitors on
(C) CRP-mediated protein expression of the kinases and (D) CRP-mediated protection of dexamethasone-induced apoptosis in myeloma cells
(MM.1S). LY249002 (L; 50 mM) and wortmannin (W; 1 mM) are PI3K-specific inhibitors, PD98059 (P; 50 mM) is an inhibitor for MEK1/2, I (15 mM) is
an inhibitor for IkBa phosphorylation, andN (18 mM) is an inhibitor for NF-kB translocation into nuclei. The concentrations of the inhibitors were chosen
based on the manufacturer’s recommendations and our preliminary tests. In these experiments, myeloma cells (ARP-1) were cultured with the inhib-
itors at the final concentrations indicated with or without dexamethasone and/or CRP for 180 min (all kinases were activated) and cell lysates were
prepared for western blot analysis (C), or for 48 hr and harvested for apoptosis (Annexin V-binding) assay (D). Representative experiment of three
performed are shown. Similar results are obtained with other myeloma cell lines and primary myeloma cells. Error bars, SEM.that CRP activated PI3K/Akt, ERK, and NF-kB in treated
cells via binding to these receptors, which led to inhibited
activation of caspase cascades induced by chemother-
apy drugs such as dexamethasone and undermined the
therapeutic efficacy of chemotherapy in the myeloma
mouse models (Figure S4). Thus, our study demonstrates
that CRP plays an active role in regulating tumor cell
growth and survival.
FcgRs are expressed by various types of cells of the im-
mune systemand have a central role in controlling immune260 Cancer Cell 12, 252–265, September 2007 ª2007 Elsevierresponses after interaction with antigen-antibody com-
plexes (Xiu et al., 2002). The activation cascade through
ITAM-associated FcgRs results in cellular activation, while
ITIM-associated FcgRs, mainly FcgRIIB in humans, medi-
ate the inhibition of the ITAM-induced activation cascade
(Xiu et al., 2002) and generate an apoptotic signal in B cells
(Ashman et al., 1996; Ono et al., 1997). CRP shares several
functional properties with IgG and binds to FcgRs. How-
ever, CRP binds primarily to the low-affinity IgG FcgRIIA
(Bharadwaj et al., 1999; Stein et al., 2000) and to someInc.
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Marnell et al., 1995). These findings are consistent with
our results that FcgRIIs serve as the major receptors for
CRP on myeloma cells. Moreover, our study also provides
data demonstrating that CRP appears to predominantly
bind FcgRIIA and FcgRIIC. No binding of CRP to the inhib-
Figure 6. Elucidation of CRP-Induced Antiapoptotic Path-
ways in Myeloma Cells
Western blot analysis showing protein levels of (A) pro- and cleaved
caspases and PARP and (C) mitochondria-related pro- and antiapop-
totic proteins in myeloma cells MM.1S treated with or without (medium
control) dexamethasone (10 mM) in the absence or presence of CRP
(25 mg/ml). Also shown are densitometric data (AVG) of (B) pro- and
cleaved caspases and PARP and (D) mitochondria-related pro- and
antiapoptotic proteins in the myeloma cells. The protein levels of b-ac-
tin served as loading control. h, hour(s). Representative experiment of
four performed are shown. Similar results are obtained with other
myeloma cell lines and primary myeloma cells. *p < 0.05; **p < 0.01.
Error bars, SEM.Cancitory FcgRIIB was detected. These observations are espe-
cially interesting because they provide a plausible expla-
nation for our observed phenomena that CRP uniformly
protected myeloma cells from apoptosis even though
some myeloma cells such as MM1-144 and a few primary
myeloma cells expressed FcgRIIB. Based on the results, it
is reasonable to expect that CRP mainly triggers an acti-
vating and antiapoptotic signaling in myeloma cells via
binding the activating FcgRII.
CRP is an acute-phase protein secreted by hepatocytes
in response to inflammatory cytokines such as IL-1 and
IL-6 (Agrawal et al., 2001; Mazer and Rabbani, 2004). In-
terestingly, higher levels of these cytokines are associated
with MM (Sirohi and Powles, 2004) and other tumors
(Gause et al., 1994; Kato et al., 1996) and may be respon-
sible for the elevated production and secretion of CRP in
the patients (Legouffe et al., 1998). As IL-6 is a survival
factor for myeloma tumor cells (Kawano et al., 1988), we
examined the relationship of IL-6 and CRP in protecting
myeloma cells from apoptosis. Our results showed that
although CRP and dexamethasone upregulated myeloma
cell secretion of IL-6, IL-6 was not responsible for CRP-
mediated protection. However, IL-6 and CRP exerted an
additive effect in protecting myeloma cells from dexa-
methasone-induced apoptosis. Thus, it is plausible that
the vicious circle of myeloma and its protective microenvi-
ronment (Sirohi and Powles, 2004) involves IL-6, CRP,my-
eloma cells, and stromal cells. Myeloma and stromal cells
secrete IL-1 and IL-6, which induce hepatocytes to pro-
duce and secrete CRP. CRP protects myeloma cells from
apoptosis induced by insults or chemotherapy drugs and
stimulates myeloma cells to secrete more IL-6, which in
turn provides additional protection to myeloma from apo-
ptosis and stimulates hepatocytes to secrete more CRP.
Thus, CRP could be a therapeutic target for breaking the
vicious circle of myeloma to improve the therapeutic effi-
cacy of currently available treatments.
EXPERIMENTAL PROCEDURES
Cell Lines, Primary Tumor Cells, and Reagents
Myeloma cell lines ARP-1 and ARK were established at the Arkansas
Cancer Research Center from bone marrow aspirates of patients
withMM (Hardin et al., 1994). MM.1S andMM.1Rwere kindly provided
by Dr. Steven Rosen from Northwestern University, Chicago, IL. Other
myeloma cell lines were purchased from ATCC (Rockville, MD).
Primary myeloma cells were isolated from bone marrow aspirates ob-
tained from patients during a routine clinic visit. CD138+ myeloma cells
were isolated by magnetic bead sorting (Miltenyi Biotec GmbH, Ber-
gisch Gladbach, Germany). The study was approved by the Institu-
tional Review Board at The University of Texas M.D. Anderson Cancer
Center. Dexamethasone and melphalan were purchased from Sigma
(St. Louis, MO). IL-6 and IL-6 receptor blocking antibodies and re-
combinant IL-6 were purchased from R&D Systems. F(ab0)2 Prepara-
tion Kit (Pierce, Rockford, IL) was used to prepare F(ab0 )2 fragments of
antibodies when they were commercially available as purified IgG.
Cell Proliferation Assay
Myeloma cells (1 3 105/ml) were cultured in complete medium
(RPMI-1640 supplementedwith 10% fetal calf serum, 1mMglutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin) containing different
concentrations of CRP for 48 hr, and cell proliferation was determineder Cell 12, 252–265, September 2007 ª2007 Elsevier Inc. 261
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CRP on Established Myeloma in SCID
or SCID-hu Mouse Models
Mice were xenografted subcutaneously with
ARP-1 (A and B) or MM.1S (C and D), and
tumor burdens were monitored as tumor
volumes. When palpable tumors (R 10 mm in
diameter) developed, mice were treated with
intraperitoneal injections of either dexametha-
sone (1 mg per mouse daily for 6 consecutive
days; [A] and [C]) or melphalan (0.5 mg per
mouse daily for 6 consecutive days; [B] and
[D]), or PBS. In some mice, CRP (200 mg per
mouse) was injected subcutaneously (around
tumors) prior to each chemotherapy treatment.
Results from one representative experiment
with 5 mice per group of three performed are
shown. (E) In SCID-hu mice (3 per group), pri-
mary myeloma cells from patients (n = 3) were
directly injected to implanted human bones,
and tumor growth was monitored as levels of
circulating human M-protein or its light chain.
Myeloma-bearing SCID-hu mice received the
same treatment as SCID mice. *p < 0.05;
**p < 0.01. Error bars, SEM.by 3H-thymidine incorporation assay. Experiments were performed in
triplicate.
Flow Cytometry Analysis
Expression of FcgRs was determined by direct immunofluorescence
using FITC- or PE-conjugated antibodies against the different FcgRs.
After staining, cells were resuspended in PBS and analyzed by aFACS-
can flow cytometer (Becton Dickinson).
Apoptosis Assays
Cells were incubated with or without the addition of various concentra-
tions of CRP for different times. The fraction of apoptotic cells was
determined by staining cells, suspended in Annexin-V binding buffer
(PharMingen), with FITC-conjugatedAnnexin-V andPI according to the
manufacturer’s instructions. After 15min of incubation at room temper-
ature, samples were analyzed by flow cytometry. Apoptotic cells were
determined as Annexin-V-positive cells. In some experiments, specific
apoptosis (% of control) was used for data presentation, calculated as
follows: [(% of apoptotic cells after a treatment % of apoptotic cells
in medium)/(% of apoptotic cells after dexamethasone treatment %
of apoptotic cells in medium)] 3 100% (Solier et al., 2002).
Cell apoptosis induced by CRP was also analyzed by TUNEL assay.
A flow cytometry-based cell death detection kit (APO-BrdU) was
purchased from BD PharMingen, and experiments were performed
according to the manufacturer’s protocol. In situ TUNEL assay was262 Cancer Cell 12, 252–265, September 2007 ª2007 Elsevier Iperformed on tumor sections to detect apoptosis in tumors isolated
from SCID mice, according to the manufacturer’s instructions.
ELISA for IL-6
Supernatants from cell cultures with or without the addition of dexa-
methasone (10 mM) and/or CRP (25 mg/ml) were collected after cul-
turing for 48 hr, and the amounts of IL-6 in the supernatants were
quantified using a commercially available ELISA kit (R&D Systems).
Generation of Osteoclasts and BMSCs, and Coculture
with Myeloma Cells
The method for generating osteoclasts has been described previously
(Yaccoby et al., 2004). PBMCs were cultured in 24-well plates in a-
MEM medium supplemented with 10% fetal calf serum, antibiotics,
RANK ligand (50 ng/ml), human M-CSF (25 ng/ml), and 10 nM dexa-
methasone for 10 to 14 days to generate tartrate-resistant acid phos-
phatase (TRAP)+ and vitronectin receptor+ osteoclasts. Before cocul-
ture, osteoclasts were washed, and freshly isolated myeloma plasma
cells from patients (0.5 3 106 cells/ml) were added to the wells and
cocultured with osteoclasts, with or without the addition of melphalan
and/or CRP. BMSCs were generated from bone marrow mononuclear
cells from patients with myeloma as described previously (Uchiyama
et al., 1993). After an adherent cell monolayer formed, these cells were
used for coculture with myeloma cells. At the end of the studies, mye-
loma cells were detached from osteoclasts or BMSCs and subjected
to analysis for apoptosis.nc.
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Formalin-fixed, paraffin-embedded sections of bone marrow biopsies
from myeloma patients or tumors from SCID mice were deparaffinized
with xylene and rehydrated to water through a graded alcohol series.
Endogenous peroxidase activity was quenched with 3% hydrogen
peroxide. Malignant plasma cells were identified by morphologic as-
sessment. Binding of CRP to myeloma cells, expression of pAkt and
pERK, and cleaved caspase-3 and -9 were detected using specific an-
Figure 8. In Vivo Validation of Signaling and Apoptosis
Mechanisms
(A) Myeloma (ARP-1)-bearing mice were injected subcutaneously
(around tumors) with CRP (200 mg per mouse) or PBS and sacrificed
24 hr later. Tumors were removed for immunohistochemical staining
for CRP, phosphorylated Akt (pAkt) and pERK;
(B) Myeloma (ARP-1)-bearing mice were injected intraperitoneally with
dexamethasone (1 mg per mouse). Prior to each chemotherapy, CRP
(200 mg per mouse) was injected subcutaneously (around tumors) to
some mice (Dex + CRP). Mice were sacrificed 24 hr later after the sec-
ond chemotherapy. Tumors were removed for immunohistochemical
staining for apoptotic cells detected by in situ TUNEL assay, cleaved
caspase-9 (cCasp-9), and caspase-3 (cCasp-3). Representative
results of three experiments are shown. Scale bar, 20 mM.Canctibodies. Detection of signal was achieved using secondary biotiny-
lated antibodies and streptavidin/horseradish peroxidase. Chromagen
3,3-diaminobenzidine/H2O2 (DAKO) was used and slides were coun-
terstained with hematoxylin. All slides were observed with light micros-
copy, and images were captured with a SPOT RT camera (Diagnostic
Instruments, Burlingame, CA).
Western Blotting
Cells were cultured with or without CRP (25 mg/ml) for different times,
harvested, washed, and lysed with lysis buffer (50 mM Tris, pH 7.5,
140 mM NaCl, 5 mM EDTA, 5 mM NaN3, 1% Triton X-100, 1% NP-
40, 1 3 protease inhibitor cocktail). Cell lysates were subjected to
SDS-PAGE, transferred to polyvinylidene difluoride membrane, and
immunoblotted with antibodies against caspase-3, -7, -8, -9, PARP,
Bcl-2, Bcl-XL, Bad, Bax, Akt, or ERK1/2, p38, JNK, FcgRIIA, FcgRIIB,
and FcgRIIC (Cell Signaling Technology, Inc., Beverly. MA, and Santa
Cruz Biotechnology). The membrane was stripped and reprobed with
anti-b-actin antibody (Sigma) to ensure equal protein loading. Second-
ary antibodies conjugated to horseradish peroxidase were used for
detection and followed by enhanced chemiluminescence (Pierce Bio-
technology) and autoradiography. For protein quantification, blots
were scanned and analyzed by spot densitometry, and results are ex-
pressed as average value of pixels enclosed (AVG). AVG is calculated
as the sum of all the pixel values after background correction divided
by area.
Immunoprecipitation
Myeloma cells were incubatedwith CRP (25 mg/ml) for 30min, washed,
and lysed in 1 ml RIPA buffer (10 mM Tris-HCL buffer, pH 7.5, 1% NP-
40, 0.25% deoxycholate wt/vol, 2 mM EDTA, 10 mM orthovanadate).
Cell lysates were precipitated with goat antibodies against CRP
(R&D Systems) or FcgRs (Santa Cruz Biotechnology) and protein G-
Sepharose, which had been preabsorbed with purified goat IgG, in a
50% wt/vol slurry. Immunoprecipitated proteins were washed in RIPA
buffer, subjected to SDS-PAGE, and immunoblotted with specific
antibodies against CRP or FcgRs.
RNA Interference
siRNAs corresponding to human FcgRIIs were purchased from Dhar-
macon (Lafayette, CO). Cells were harvested, plated on a 24-well plate
at a concentration of 2 3 105 cells per well and 24 hr later, transiently
transfected with specific siRNAs or nonspecific/control siRNA using
the Oligofectamine transfection reagent (Mirus, Madison, WI) accord-
ing to the manufacturer’s instructions. Three days after the transfec-
tion, cells were harvested to examine FcgR protein expression or used
for experiments.
Animal Studies
CB.17 SCID mice were purchased from Harlan (Indianapolis, IN). All
mice were maintained in American Association of Laboratory Animal
Care-accredited facilities, and studies were approved by the Institu-
tional Animal Care and University of Texas M.D. Anderson Cancer
Center. Six- to eight-week-old female CB.17 SCID mice were subcu-
taneously inoculated in the right flank with 1 3 106 ARP-1 or MM.1S
cells in 50 mL RPMI-1640 medium. Three to five weeks later when pal-
pable tumors (R 10 mm in diameter) developed, mice (n = 5 for all
groups, the same experiments were repeated three times) were intra-
peritoneally injected with dexamethasone (1 mg per mouse) or mel-
phalan (0.5mgpermouse) daily for 6 consecutive days. To examine the
effects of CRP on tumor cells, some mice also received subcutaneous
(around tumors) injections of CRP (200 mg per mouse) prior to each
treatment with dexamethasone or melphalan. Control mice were in-
jected intraperitoneally with equal volumes of PBS. Tumor size was
measured every day in two dimensions using a caliper, and tumor vol-
ume (mm3) was calculated as 4p/33 (tumor width/2)23 (tumor length/
2) (LeBlanc et al., 2002). Serumwas also collected frommice daily dur-
ing the treatment and tested for myeloma-secretedM-proteins (human
immunoglobulins) or their light chains by ELISA. Mice were humanelyer Cell 12, 252–265, September 2007 ª2007 Elsevier Inc. 263
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15 mm in diameter.
The SCID-hu mouse model was established in CB.17 SCID mice as
previously described (Yaccoby et al., 1998). Freshly isolated primary
myeloma cells (1 3 106/mouse) from patients were directly injected
to implanted human bones and once myeloma was established (circu-
lating human M-proteins or their light chains reaching R40 mg/ml),
treatment with dexamethasone began, which was the same as for
SCID mice. Serum was collected from mice daily during the treatment
and tested for myeloma-secreted M-proteins (human immunoglobu-
lins) or their light chains by ELISA.
Statistical Analysis
All data are shown as means ± SEM. The Student’s t test was used to
compare various experimental groups; significance was set at p less
than 0.05.
Supplemental Data
The Supplemental Data include four supplemental figures and can be
found with this article online at http://www.cancercell.org/cgi/content/
full/12/3/252/DC1/.
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